Serum antibodies against prostasomal clusterin in prostate cancer patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 3, 2008, Pages 219-227

  Ronquist, K G ^a   Carlsson, L ^a   Ronquist, G ^a   Semjonow, A ^b   Wulfing C ^b   Larsson, A ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antibodies; Clusterin; Prostasomes; Prostate cancer

Indexed keywords

ANTIBODY; CLUSTERIN; CLUSTERIN ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROTITER PLATE ASSAY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CLUSTERIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 43049144584     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701604602     Document Type: Article

References (33)

1. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002;34:1430-48.
2. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004;64:1834-42.
3. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004;23:2298-304.
4. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005;23:38-46.
5. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, et al. Prevention of cell death induced by tumour necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 1995;55:2431-7.
6. Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, et al. Cytotoxic sensitivity to tumour necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 1999;39:87-93.
7. Caccamo AE, Scaltriti M, Caporali A, D'Arca D, Scorcioni F, Astancolle S, et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem J 2004;382:157-68.
8. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res 2004;64:6174-82.
9. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002;8:3276-44.
10. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prost Cancer Prost Dis 2004;7:243-8.
11. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Upsala J Med Sci 2001;106:43-50.
12. Larsson A, Ronquist G, Wulfing C, Eltze E, Bettendorf O, Carlsson L, et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 2006;24:195-200.
13. Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta 1985;822:203-18.
14. Sahlen G, Ahlander A, Frost A, Ronquist G, Norlen BJ, Nilsson BO. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004;61:291-7.
15. Carlsson L, Nilsson O, Larsson A, Stridsberg M, Sahlen G, Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate 2003;54:322-30.
16. Ronquist KG, Carlsson L, Ronquist G, Nilsson S, Larsson A. Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer 2006;119:847-53.
17. Murphy BF, Kirszbaum L, Walker ID, dÁpice AJF. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest 1988;81:1858-64.
18. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992;4:129-38.
19. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-45.
20. Jenne DE, Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992;17:154-9.
21. Collard MW, Griswold MD. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry 1987;26:3297-303.
22. Leger JG, Montpetit ML, Tenniswood MP. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem Biophys Res Commun 1987;147:196-203.
23. Kadomatsu K, Anzano MA, Slayter MV, Winokur TS, Smith JM, Sporn MB. Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. Cancer Res 1993;53:1480-3.
24. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumour grade in prostate cancer. Clin Cancer Res 1997;3:1707-11.
25. Morrissey C, Lakins J, Moquin A, Hussain M, Tenniswood M. An antigen capture assay for the measurement of serum clusterin concentrations. J Biochem Biophys Methods 2001;48:13-21.
26. Burkey BF, deSilva HV, Harmony JA. Intracellular processing of apolipoprotein J precursor to the mature heterodimer. J Lipid Res 1991;32:1039-48.
27. Kirszbaum L, Sharpe JA, Murphy B, d'Apice AJ, Classon B, Hudson P, et al. Molecular cloning and characterization of the novel, human complement- associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J 1989;8:711-18.
28. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, et al. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/ clusterin. J Biol Chem 1995;270:232-4.
29. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993;293:27-30.
30. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990;29:5380-9.
31. Tsuruta JK, Wong K, Fritz IB, Griswold MD. Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to clusterin and serum protein 40,40. Biochem J 1990;268:571-8.
32. Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989;86:7123-7.
33. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Chinnaiyan AM, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.